Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

Altered histone deacetylase (HDAC) activity has been identified in several types of cancer. This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Twenty-six pre-treated patients with progressing solid tumours...

Descripción completa

Detalles Bibliográficos
Autores principales: Atmaca, A, Al-Batran, S-E, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B, Schwarz, S E, Hövelmann, S, Göttlicher, M, Knuth, A, Jäger, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360302/
https://www.ncbi.nlm.nih.gov/pubmed/17579623
http://dx.doi.org/10.1038/sj.bjc.6603851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360302/
https://www.ncbi.nlm.nih.gov/pubmed/17579623
http://dx.doi.org/10.1038/sj.bjc.6603851

Ejemplares similares